By Stan Choe, Damian J. Troise, and Alex Veiga

Stocks around the world whipped higher Wednesday, riding a wave of optimism on encouraging data about a possible treatment for COVID-19.

The upswell of hope was so strong that investors completely sidestepped a report showing the outbreak drove the U.S. economy to its worst quarterly performance since the Great Recession. The S&P 500 vaulted 2.7% higher and extended a rally that’s brought the U.S. stock market to the brink of its best month in 45 years.

The spark for Wednesday’s rally was a report that an experimental drug proved effective against the new coronavirus in a study run by the National Institutes of Health. The nation’s top infectious diseases expert said the drug reduced the time it takes patients to recover, and it raised hopes that life around the world may eventually tiptoe back toward “normal.”

The S&P 500 rose 76.12 points to 2,939.51. It has surged 13.7% in April, and it’s a day away from closing out its best month since late 1974.

The Dow Jones Industrial Average rose 532.31, or 2.2%, to 24,633.86, and the Nasdaq climbed 306.98, or 3.6%, to 8,914.71.

“What you’re finding now is you have this debate between optimism and realism,” said Adam Taback, chief investment officer for Wells Fargo Private Wealth Management.

The Federal Reserve said Wednesday that it expects the health crisis to weigh on the economy “over the medium term,” as it promised to keep in place massive amounts of aid and interest rates at nearly zero. Oil prices, bonds, and other markets besides stocks have also been dominated in recent weeks by worries about the economic impact of the virus outbreak.

“Everything except equities is telling you things are not great,” Taback said. “This market is overly optimistic.”

Gilead’s release about its remdesivir drug hit markets at the same moment as a government report showing the U.S. economy shrank at a 4.8% annual rate in the first three months of the year.

Job losses have exploded since early April, as layoffs sweep the nation following widespread stay-at-home orders, and economists expect to see even worse numbers for the second quarter of the year.

The first-quarter figure was “merely the tip of the iceberg,” said Michael Reynolds, investment strategy officer at Glenmede.

But stocks have been rallying over the last month as investors look beyond the current economic devastation and focus instead on the prospect of economies gradually reopening. Some U.S. states and nations around the world have laid out plans to relax restrictions keeping people at home and businesses bereft of customers. Any new treatment for COVID-19 could also lower the dread so prevalent among households and businesses around the world.

But what got the 31.4% rally for the S&P 500 started in late March was massive aid from the Federal Reserve and Congress. The Fed on Wednesday said it wouldn’t be pulling back on the aid anytime soon.

The market’s easing pessimism about the economy’s path is perhaps most clear in how the smallest stocks have been performing.

When recession worries were at their height, investors punished small-cap stocks and sent them to sharper declines than the rest of the market, in part on worries about their more limited financial resources. But the Russell 2000 index of small-cap stocks jumped 4.8% Wednesday. It’s up 10.4% this week alone, more than double the gain for indexes of bigger stocks.

The market’s gains were widespread and accelerated throughout the day. Big tech and communications stocks helped lead the way after Google’s parent company said its revenue was stronger in the first three months of the year than Wall Street was expecting.

Alphabet jumped nearly 9%, which helped communications stocks in the S&P 500 rise 5% for one of the biggest gains among the 11 sectors that make up the index.

In Europe, the French CAC 40 rose 2.2% after being down before the Gilead report. The German DAX returned 2.9%, and the FTSE 100 in London added 2.6%. In Asia, Hong Kong’s Hang Seng added 0.3%, and the Kospi in Seoul advanced 0.7%.

Many professional investors are skeptical of the U.S. stock market’s big rally. There’s still a lot of uncertainty about how long the recession will last.

The vigorous rise for stocks over the last month also implies investors see a relatively quick rebound for the economy and profits following the current devastation. But it may take a while for households and businesses to get back to how things used to be.

“My concern is that the market is starting to get a little bit more focused on the rewards and less focused on the risks right now,” said Sal Bruno, chief investment officer at IndexIQ. “Maybe investors are getting a little too enthusiastic.”

“I don’t think you just flip the switch and everybody goes back to work right away,” he said.

The yield on the 10-year U.S. Treasury rose to 0.62% from 0.61% late Tuesday after paring earlier losses. Yields tend to rise when investors are upgrading expectations for the economy and inflation.

Oil prices are continuing their extreme swings after a collapse in demand has sent crude storage tanks close to their limits. Benchmark U.S. crude oil for June delivery rose $2.72, or 22%, to settle at $15.06 a barrel Wednesday. Brent crude oil, the international standard, rose $2.08, or 10.2%, to $22.54 a barrel.

___

AP Business Writer Joe McDonald contributed.

Share:
More In Business
Little Otter Raises $22 Million Series A to Combat the Children's Mental Health Crisis
Digital mental health company Little Otter recently announced it closed a $22 million Series A round. Little Otter was founded in 2020 by a mother-daughter team, which based the company on the idea that a child's mental health can only be addressed by treating the whole family through technology available to everyone. Little Otter CEO and co-founder Rebecca Egger and her mother, Little Otter Chief Medical and Scientific Officer and co-founder Dr. Helen Egger joined Cheddar News' Closing Bell to discuss.
Stocks Close Lower as Rate Hike Fears Hit Tech Stocks
Stocks closed lower Thursday with the tech-heavy Nasdaq in particular under pressure as investors dump tech stocks amid interest rate hike fears. This is the third session in a row that the Nasdaq has slipped. Meanwhile, rate-sensitive stocks gained one day after the Federal Reserve announced its more hawkish policy including three rate hikes this year. Kristina Hooper, Chief Global Market Strategist at Invesco, joins Cheddar News' Closing Bell to discuss today's close, this week's Fed minutes and the central bank's new hawkish policy, and more.
Health Tech Like Abbott Biowearable Lingo Take CES Center Stage
Jared Watkin, senior vice president, diabetes care, at Abbott Laboratories, joined Michelle Castillo from the CES 2022 floor to discuss the future of health tech, including Abbott's consumer-facing biowearable called Lingo. The accessory is supposed to send real-time biomarker information like glucose or ketone levels to the Lingo app for the wearer to review. "The idea is that it's a window into your body," Watkin said. "It gives you insight into what's going on in your body and the certain circumstances that you otherwise wouldn't be able to have."
LIDAR Tech Firm Luminar Partners With Volvo to Advance Safe Autonomous Driving
Aaron Jefferson, VP of product at Luminar, joined Cheddar to discuss partnering with automaker Volvo to bring its LIDAR (light detection and ranging) tech into autonomous cars capable of safely driving on the highway. While companies like Tesla have come under fire due to safety issues with its self-driving technology, Jefferson noted how his company's tech differs. "Our LIDAR, its iris sensor that's really set for production, is able to sense, understand, and give the vehicle confidence to react accordingly such that you don't have these same types of issues," he said. The Ride Pilot technology in Volvo vehicles will be rolled out in California following safety testing.
Mark Cuban-Backed Fintech App Dave on Disrupting Banking as It Goes Public
The fintech app backed by billionaire Mark Cuban called Dave made its public debut on the Nasdaq Thursday via a SPAC merger. CEO and co-founder Jason Wilk spoke to Cheddar's Kristen Scholer about the IPO and how his company's services distinguish it from traditional banks. "Customers come to us because they're tired of paying $20 billion of overdraft fees, and they come to Dave, they download our app, and within minutes they can get access to $250 of no interest credit, which we give them through our own proprietary machine learning model," he told Cheddar.
Marriott Design Lab for Hotel Tech Innovation Announced at CES 2022
Stephanie Linnartz, president of Marriott International, joined Cheddar's "Closing Bell" to talk about the launch of the Marriott Design Lab, a new facility within its Bethesda, Maryland, headquarters to explore innovative tech offerings for bolstering the guest experience. "It's all around figuring out how we can innovate in the guest room in the public space, looking at how we can use robotics, improve sustainability, etcetera," she said. Some short-term changes in the future Linnartz also noted is an expansion of the chain's mobile capabilities to make check-in and check-out an easier process for guests, as well as mobile room service, from the feedback it received during the pandemic.
NFT Industry Growth in 2021
The NFT craze took off in 2021 and shows no signs of slowing down in 2022. Cheddar News takes a closer look at what helped push the industry forward.
Nike, AMEX Among Companies Sticking to Pledge to Not Fund January 6 Objectors
Following the attack on the Capitol last year, several major corporations promised to no longer pour funds into the campaigns of Republican lawmakers who supported the January 6 insurrection. But not all have stood firm on their word. Among those that did keep to their promise were Nike, American Express, and Walgreens.
Load More